Presentation at RNA Therapeutics conference

RNS REACH

16 February 2015

Silence Therapeutics plc

Presentation at RNA Therapeutics conference

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the development and delivery of novel RNA therapeutics will be presenting at RNA Therapeutics, the international RNA sector conference, in London on 16-17 February. No new material information will be disclosed by the Company.

Executive Director, Dr Mike Khan, will be giving a presentation on 'RNAi Therapeutics: Opportunities, obstacles and solutions', and will be chairing the second day of the conference as well as hosting a panel debate.

Silence is also a main sponsor of the RNA Therapeutics conference. For more information, please see http://www.smi-online.co.uk/pharmaceuticals/uk/conference/rnai-nano-technology

Enquiries:

About Silence Therapeutics (www.silence-therapeutics.com)

Silence Therapeutics is a leading RNA therapeutics company. It has developed proprietary modifications to improve the robustness of RNA sequences together with advanced liposomal chemistries to enhance the delivery of its therapeutics. Its technology can selectively silence or replace the expression of any gene in the genome, modulating expression up as well as down in a variety of organs and cell types, in vivo. This allows the development of therapeutics for diseases with high unmet clinical need. Silence's technology is currently in the clinic in a Phase 2a pancreatic cancer trial.